Biojo Sciences

Executive Summary

Biojo Sciences is a San Diego-based contract development and manufacturing organization (CDMO) founded in 2019, dedicated to partnering with visionary biotech companies from preclinical through clinical stages. The company bridges the gap between breakthrough science and commercial reality, offering expertise across oncology, rare diseases, cell and gene therapies, and AI-driven platforms. With a focus on navigating the complexities of drug development, Biojo provides critical support to innovators, enabling them to advance their pipelines efficiently. As a private, pre-clinical stage company with no disclosed funding or valuation, BSI is positioned to capitalize on the growing demand for outsourced drug development services, particularly in high-growth therapeutic areas. Its success hinges on its ability to attract and retain top-tier biotech clients, execute on development milestones, and potentially expand its own capabilities through strategic investments or partnerships.

Upcoming Catalysts (preview)

• Q2 2026Announcement of Major Partnership with AI-Driven Biotech70% success
• Q4 2026Completion of Facility Expansion to Increase GMP Capacity60% success
• Q3 2026First Client Program Reaches Phase I Clinical Trial Start50% success